| 17.59 0 (0%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.83 | 1-year : | 21.1 |
| Resists | First : | 17.84 | Second : | 18.06 |
| Pivot price | 17.59 | |||
| Supports | First : | 17.46 | Second : | 14.53 |
| MAs | MA(5) : | 17.59 | MA(20) : | 17.59 |
| MA(100) : | 17.34  |
MA(250) : | 16.57  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20 | D(3) : | 20 |
| RSI | RSI(14): 48.9 | |||
| 52-week | High : | 24.14 | Low : | 9.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZEAL ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.11 - 18.2 | 18.2 - 18.27 |
| Low: | 17.23 - 17.35 | 17.35 - 17.44 |
| Close: | 17.42 - 17.6 | 17.6 - 17.75 |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Fri, 19 Apr 2024
Zealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and ... - GlobeNewswire
Fri, 19 Apr 2024
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities ... - GlobeNewswire
Sun, 31 Mar 2024
Total number of shares and voting rights in Zealand Pharma at March 31, 2024 - Yahoo Finance
Tue, 26 Mar 2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - GlobeNewswire
Tue, 19 Mar 2024
Zealand Pharma major shareholder announcement: Polar Capital - Yahoo Finance
Thu, 07 Mar 2024
Zealand Pharma stock get Buy from BTIG on obesity pipeline promise - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 76 (K) |
| Shares Short P.Month | 77 (K) |
| EPS | -3.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.94 |
| Profit Margin | 0 % |
| Operating Margin | -336.2 % |
| Return on Assets (ttm) | -31.7 % |
| Return on Equity (ttm) | -80.7 % |
| Qtrly Rev. Growth | 164.3 % |
| Gross Profit (p.s.) | 4.02 |
| Sales Per Share | 6.98 |
| EBITDA (p.s.) | -22.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,160 (M) |
| Levered Free Cash Flow | -831 (M) |
| PE Ratio | -4.92 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 2.51 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|